Number of positive lymph nodes and lymphatic invasion are significant prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma

References

• Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: french experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg. 2000;7(2):128–134.10982604
   PubMedGoogle Scholar
• Von Hahn T, Ciesek S, Wegener G, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46(9):1092–1098. doi:10.3109/00365521.2011.58947221692710
   PubMed Web of Science ®Google Scholar
• Andrianello S, Paiella S, Allegrini V, et al. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long–term follow–up. Langenbecks Arch Surg. 2015;400(5):623–628. doi:10.1007/s00423-015-1320-026134446
   PubMed Web of Science ®Google Scholar
• Kiriyama M, Ebata T, Aoba T, et al. Nagoya Surgical Oncology Group. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg. 2015;102(4):399–406. doi:10.1002/bjs.975225611179
   PubMed Web of Science ®Google Scholar
• Kim YS, Hwang IG, Park SE, et al. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemother Pharmacol. 2016;77(5):979–985. doi:10.1007/s00280-016-2970-527017615
   PubMed Web of Science ®Google Scholar
• Choi SB, Park SW, Kim KS, Choi JS, Lee WJ. The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol. 2009;99(6):335–342. doi:10.1002/jso.v99:619226533
   PubMed Web of Science ®Google Scholar
• Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013;60(128):1892–1895.24719923
   PubMedGoogle Scholar
• Qiao QL, Zhang TP, Guo JC, et al. Prognostic factors after pancreatoduodenectomy for distal bile duct cancer. Am Surg. 2011;77(11):1445–1448.22196654
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese society of hepato–biliary–pancreatic surgery: 3rd English edition. J Hepatobiliary Pancreat Sci. 2015;22(3):181–196. doi:10.1002/jhbp.22325691463
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Miyakawa S, Nagino M, Takada T, Miyazaki M. Revision concepts and distinctive points of the new Japanese classification for biliary tract cancers in comparison with the 7(th) edition of the Union For International Cancer Control and the American Joint Committee on Cancer staging system. J Hepatobiliary Pancreat Sci. 2015;22(3):197–201. doi:10.1002/jhbp.22325624072
   PubMed Web of Science ®Google Scholar
• Androulakis J, Colborn GL, Skandalakis PN, Skandalakis LJ, Skandalakis JE. Embryologic and anatomic basis of duodenal surgery. Surg Clin North Am. 2000;80(1):171–199. doi:10.1016/S0039-6109(05)70401-110685148
   PubMed Web of Science ®Google Scholar
• Ercolani G, Dazzi A, Giovinazzo F, et al. Intrahepatic, peri–hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors? Eur J Surg Oncol. 2015;41(9):1162–1169. doi:10.1016/j.ejso.2015.05.01326095704
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kim SG, Chun JM, Lee WK, Hwang YJ. Prognostic factors in patients with middle and distal bile duct cancers. World J Gastroenterol. 2014;20(21):6658–6665. doi:10.3748/wjg.v20.i21.665824914391
   PubMed Web of Science ®Google Scholar
• Courtin–Tanguy L, Rayar M, Bergeat D, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016;113(5):575–580. doi:10.1002/jso.2416526776934
   PubMed Web of Science ®Google Scholar
• Komaya K, Ebata T, Shirai K, et al. Nagoya surgical oncology group. recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104(4):426–433. doi:10.1002/bjs.1045228138968
   PubMed Web of Science ®Google Scholar
• Wellner UF, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta–analysis for the 5–year survival. Surg Today. 2017;47(3):271–279. doi:10.1007/s00595-016-1362-027236779
   PubMed Web of Science ®Google Scholar
• Sasaki R, Takeda Y, Funato O, et al. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg. 2007;31(9):1788–1796. doi:10.1007/s00268-007-9102-717647056
   PubMed Web of Science ®Google Scholar
• Wakai T, Sakata J, Katada T, et al. Surgical management of carcinoma in situ at ductal resection margins in patients with extrahepatic cholangiocarcinoma. Ann Gastroenterol Surg. 2018;2(5):359–366. doi:10.1002/ags3.1219630238077
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Friederichs J, Schuster T, et al. Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3026 patients over a 25-year time period. Ann Surg. 2008;248(6):968–978. doi:10.1097/SLA.0b013e318185571819092341
   PubMed Web of Science ®Google Scholar
• Schiffman SC, McMasters KM, Scoggins CR, Martin RC, Chagpar AB. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. J Am Coll Surg. 2011;213(1):45–52. doi:10.1016/j.jamcollsurg.2011.04.02421601490
   PubMed Web of Science ®Google Scholar
• Kawai M, Tani M, Kobayashi Y, et al. The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. Am J Surg. 2010;199(4):447–452. doi:10.1016/j.amjsurg.2009.01.01919596119
   PubMed Web of Science ®Google Scholar
• Schrembs P, Martin B, Anthuber M, Schenkirsch G, Märkl B. The prognostic significance of lymph node size in node–positive colon cancer. PLoS One. 2018;12(8):e0201072. doi:10.1371/journal.pone.0201072
   Web of Science ®Google Scholar
• Hernandez J, Cowgill SM, Al–Saadi S, et al. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol. 2008;15(3):807–814. doi:10.1245/s10434-007-9756-218181000
   PubMed Web of Science ®Google Scholar
• Ebata T, Hirano S, Konishi M, et al. Bile Duct Cancer Adjuvant Trial (BCAT) study group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192–202. doi:10.1002/bjs.1077629405274
   PubMed Web of Science ®Google Scholar
• Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta–analysis. J Clin Oncol. 2012;30(16):1934–1940. doi:10.1200/JCO.2011.40.538122529261
   PubMed Web of Science ®Google Scholar